Clinical Trial Update: Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301 [Phase 3]

View source ↗

Summary

This is a follow-up safety study of enteric-coated mycophenolate sodium in renal transplant patients who completed the prior CERL080A301 trial, reporting safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Enteric-coated mycophenolate sodium (mycophenolate sodium)

Snippet

Sponsor: Novartis | Conditions: Renal Transplant | Phase 3 | Status: COMPLETED